Compound Guide

DSIP

DSIP after the April 15 FDA reclassification — its research base, regulatory timeline for July PCAC, safety signals, and how to source it legally.

Last reviewed May 8, 2026

Quick Summary

What it is. Delta Sleep-Inducing Peptide (DSIP) — a naturally occurring nonapeptide (nine amino acids) first isolated from the cerebral venous blood of sleeping rabbits in the 1970s. Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Most-studied research areas. Sleep architecture modulation — particularly slow-wave (delta) sleep induction — stress response, neuroprotection, stroke recovery, and anticonvulsant effects.

Current U.S. legal status (May 2026). On April 15, 2026, the FDA removed DSIP from Category 2 as part of a 12-peptide reclassification. It is now on an interim evaluation tier pending final 503A Bulks List placement at the July 23–24, 2026 PCAC meeting — one of seven peptides on that agenda. Licensed compounding pharmacies may legally fill prescriptions under a valid practitioner order.

Expected post-PCAC compounded price. $80–$160 per 5mg vial at a legitimate compounding pharmacy — among the more affordable reclassified peptides due to its small size and straightforward synthesis.

Evidence base. Research history spans five decades (1970s to present) with extensive preclinical evidence in sleep, stress, and neuroprotection. Human clinical data is limited to small studies and case series. The basic pharmacology — blood-brain barrier penetration, receptor interactions — is better characterized than for most reclassified peptides.

What Is DSIP?

DSIP — short for Delta Sleep-Inducing Peptide — was discovered in the 1970s by Swiss scientist Dr. Marcel Monnier and his colleagues at the University of Basel, who identified a sleep-promoting factor in the cerebral venous blood of rabbits during electro-sleep stimulation. By 1977, the peptide had been isolated, sequenced, and synthesized.

The nine-amino-acid sequence (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) distinguishes DSIP from virtually every other peptide on the April 15 reclassification list. It was the first endogenous sleep peptide to be fully characterized, and it remains one of the few known to preferentially promote slow-wave (delta) sleep rather than REM sleep.

DSIP is found endogenously in the mammalian brain with a widespread distribution. Immunocytochemical studies from the 1980s localized DSIP-immunoreactive neurons throughout the rat brain — in the hypothalamus, thalamus, amygdala, cerebral cortex, and brainstem — suggesting the peptide functions as a broadly distributed neuromodulator rather than a region-specific sleep factor Neuroscience, 1984.

A particularly well-documented feature is DSIP’s ability to cross the blood-brain barrier (BBB). Multiple studies demonstrated that radiolabeled DSIP traverses the BBB through a non-competitive, carrier-mediated mechanism Brain Research, 1984. This BBB permeability is not universal among peptides and gives DSIP a pharmacokinetic advantage for CNS applications.

DSIP has been detected in cerebrospinal fluid, peripheral blood, and various tissues, and has been administered intravenously, intranasally, intraperitoneally, and intracerebroventricularly in experimental models — all with measurable biological activity.

What the Research Shows

Preclinical evidence is broad but dated

The DSIP literature spans five decades, but the most heavily cited preclinical work was published between 1980 and 2004. The volume of new research has declined relative to other peptides on the reclassification list.

Key findings:

Sleep architecture. Intracerebroventricular DSIP injection in rats produced a significant (~20%) increase in total slow-wave sleep compared to sham injection Neuroscience Letters, 1983. Later work demonstrated that a phosphorylated DSIP analog restored spatial memory in rats exposed to high-altitude hypoxia by improving sleep architecture, mediated through p-CREB expression Life Sciences, 2018.

Stress response. An extensive Russian research program spanning the 1990s and early 2000s found that DSIP treatment before restraint-stress exposure in rats modulated free radical oxidation in the liver, increased catalase and superoxide dismutase activity, and altered serum aminotransferase levels Bulletin of Experimental Biology and Medicine, 2016. These findings suggest a stress-protective role at the tissue level, though whether these are direct effects or downstream consequences of improved sleep remains unclear.

Stroke recovery. A 2021 study in Molecules investigated intranasal DSIP treatment (120 µg/kg) in a rat model of focal stroke. The DSIP-treated group showed significant improvement in motor coordination and balance across 21 days compared to vehicle-treated controls Molecules, 2021.

Aging and anticonvulsant effects. A 2003 study of the DSIP-containing preparation Deltaran reported modest lifespan extension and reduced spontaneous tumor incidence in mice Mechanisms of Ageing and Development, 2003. Separately, DSIP was shown to alleviate the severity of metaphit-induced seizures in rats Pharmacology Biochemistry and Behavior, 2004.

Human clinical data is limited

As of May 2026, published randomized controlled trials of DSIP in humans are effectively absent from the peer-reviewed literature. This is the single most important limitation of the evidence base, shared to varying degrees with every other peptide on the reclassification list.

What does exist includes small human sleep studies from the 1980s and 1990s (European, predominantly Russian and German) reporting DSIP-induced increases in slow-wave sleep with minimal impact on REM architecture — though sample sizes were very small (typically N < 20) and modern polysomnographic standards were inconsistently applied. A 2009 anesthesia study found DSIP altered bispectral index, EEG patterns, and heart rate variability when used as an adjunct to propofol anesthesia, suggesting measurable CNS effects European Journal of Anaesthesiology, 2009.

Where DSIP Is Most Commonly Prescribed

In the practitioner community, DSIP is most frequently discussed for sleep quality and sleep architecture support — patients reporting non-restorative sleep, fragmented sleep, or insufficient slow-wave sleep who have not responded adequately to conventional aids. It is also used in stress adaptation protocols and, less commonly, in chronic fatigue contexts.

Prescription for indications outside sleep or stress — general “wellness” or performance enhancement — is less supported by either the available literature or practitioner consensus.

Legal and Regulatory Status

Pre-April 15, 2026

Prior to the April 15 reclassification, DSIP was listed in Category 2 of the FDA’s 503A compounding evaluation framework — designated as a substance raising significant safety concerns for compounding. Licensed compounding pharmacies could not compound DSIP at scale without drawing regulatory attention. Most consumer access came through the gray-market “research chemical” channel.

April 15, 2026 — Reclassification

On April 15, 2026, the FDA formally removed DSIP, along with 11 other peptides, from Category 2 and placed it on an interim evaluation tier. Licensed compounding pharmacies may now legally prepare DSIP under a valid prescription. The FDA has committed to a final 503A Bulks List placement decision at the July 23–24, 2026 PCAC meeting — one of seven peptides on that agenda alongside BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon.

July 23–24, 2026 — PCAC Outlook

The Pharmacy Compounding Advisory Committee will recommend final placement for DSIP. Industry expectation is mixed: DSIP’s long safety history and well-characterized pharmacology provide a foundation for approval, but the dated and limited human clinical literature may give PCAC pause. The peptide’s CNS-active properties could raise additional scrutiny around dosing standardization. Compared to BPC-157 or TB-500 — which have larger active practitioner communities and more recent research output — DSIP faces a moderately higher risk of a restricted or conditional placement recommendation. If approved, the most likely outcome is inclusion on the 503A Bulks List with ongoing post-market surveillance.

We will update this page within 72 hours of the PCAC outcome. Subscribers to the PeptidesBeat Daily Brief receive regulatory updates in real time.

State-Level Variance

Federal reclassification sets the floor; state pharmacy boards can set tighter rules. California, New York, Massachusetts, Connecticut, Illinois, Maryland, New Jersey, Hawaii, Vermont, and DC maintain more restrictive non-resident pharmacy regimes — expect extra verification steps in those states. See the state-by-state tracker for your jurisdiction.

The Research-Chemical Channel

The April 15 action clarifies the prescription pathway. It does not legitimize the gray market. DSIP purchased from a research-chemical vendor labeled “not for human consumption” is still operating outside the legal drug supply chain — regardless of the federal reclassification.

How It’s Typically Administered

Important: Nothing below is a dosing recommendation. This section describes what practitioners report as typical practice, not what you should do.

DSIP is most commonly administered by subcutaneous injection, typically in the evening to align with the body’s natural sleep-wake cycle. Intranasal administration has been studied experimentally. Some practitioners recommend cyclical protocols (e.g., 5 days on, 2 days off) to mitigate potential tolerance, though formal studies on tachyphylaxis have not been published. DSIP must be stored refrigerated and protected from light.

Reported Safety Signals

Across the available preclinical and human data, DSIP has a favorable reported short-term safety profile. No published reports of serious adverse events attributable to DSIP were identified in our review.

Reported mild adverse events include injection-site reactions (transient redness, minor swelling), transient drowsiness when administered too early in the day or at excessive dose, and altered dream patterns in a small number of anecdotal reports — no systematic data exists.

Long-term human safety data for DSIP is effectively absent, as it is for every peptide on the reclassification list. The longest published human exposure window is measured in weeks. Theoretical concerns include the possibility of unintended neuropeptide signaling disruption with prolonged exogenous DSIP administration, given the peptide’s role in endogenous sleep-wake regulation — a rational concern that relevant safety monitoring has not yet addressed.

Expected Pricing (Post-PCAC)

DSIP’s small molecular size (9 amino acids) and well-characterized synthesis make it among the most economical reclassified peptides to manufacture at compounding quality:

Form	Expected Price Range
5mg vial (lyophilized, for reconstitution)	$80–$160
10mg vial (lyophilized)	$150–$250
Pre-reconstituted solution (multiple-dose vial)	$120–$200

Research-chemical vendors typically price 30–50% lower. That price delta reflects the absence of sterility testing, potency verification, and pharmacist oversight. Independent testing of gray-market peptides has historically shown contamination rates between 20% and 60%.

How to Source It Legitimately

Establish a relationship with a peptide-familiar prescriber (MD, DO, NP, or PA). See our provider directory. Telehealth is acceptable in most permissive and moderate-tier states.
Have a documented clinical reason. For DSIP, a documented sleep quality complaint or stress-related sleep disruption provides the appropriate clinical foundation.
Identify a legitimate compounding pharmacy licensed in your state. Use our pharmacy directory. Confirm the pharmacy holds current licensure in both its home state and yours.
Request a Certificate of Analysis for your specific batch. A legitimate compounder provides this without hesitation.
Verify cold-chain shipping. DSIP should ship with cold packs.
Maintain your supervision relationship. Follow your prescriber’s check-in protocol.

Common Questions

Is DSIP FDA approved?

No. DSIP is not an FDA-approved drug for any indication. The April 15 action removed it from Category 2, allowing compounding pharmacies to prepare it under prescription — a different status than FDA approval.

Is DSIP legal in my state?

Federal reclassification permits compounding nationwide, but state pharmacy board rules vary. Ten states and DC maintain more restrictive regimes. See our state-by-state tracker.

Is DSIP safe?

Short-term reported safety is favorable. Long-term human safety data is limited. Standard practice is supervision by a licensed clinician who has screened for contraindications.

Does DSIP help with sleep?

The preclinical evidence for slow-wave sleep induction is the most consistent finding in the DSIP literature. Practitioner reports describe the most benefit for individuals with objective sleep disruption. Placebo-controlled human data for clinical sleep disorders is absent.

Can I buy DSIP online without a prescription?

Online vendors sell DSIP as a “research chemical.” This path is not legal for human use, frequently supplies contaminated product, and leaves you without a clinician of record. The legal path is prescription plus compounding pharmacy.

DSIP vs. melatonin — what’s the difference?

Melatonin is a hormone that signals the body to prepare for sleep (circadian timing). DSIP is a neuropeptide thought to modulate sleep quality and architecture, particularly slow-wave sleep. They operate through different pathways and are not interchangeable.

Semax — Another neuroactive peptide on the July 2026 PCAC agenda, studied for cognitive effects and BBB penetration.
Epitalon — A peptide on the same regulatory timeline, studied for sleep and aging-related applications.